Jason A Tri1, Christopher V DeSimone2, Craig Daniels3, Roshini S Asirvatham1, Susan B Mikell4, Dorothy J Ladewig4, Kelly Krajnick4, Samuel J Asirvatham5. 1. Mayo Clinic Summer Externship Program, Mayo Clinic, Rochester, Minnesota. 2. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 3. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota. 4. Mayo Clinic Ventures, Mayo Clinic, Rochester, Minnesota. 5. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
Abstract
OBJECTIVE: Asthma is a common disease which places significant burden on the US healthcare system and which can be associated with significant patient morbidity and mortality. Current medical therapies are costly and not curative. A new approach for a more permanent asthma treatment is the use of radiofrequency ablation. However, this radiofrequency approach is thermal-based and can result in deleterious effects to the airways, such as stenosis or ulceration. We describe a novel, improved therapeutic approach for smooth muscle ablation using non-thermal DC electroporation ablation. METHODS: We developed and tested prototype electroporation ablation devices that access the airways both endoscopically and via a bronchoscope. We tested the feasibility of this approach and demonstrated proof-of-concept in 2 mongrel dogs. In order to assess for smooth muscle function, we performed functional studies pre and post ablation with methacholine challenge to assess for airway reversibility. We also evaluated bronchial lesions via direct vision with bronchoscopy. RESULTS: We developed novel electroporation catheters to delivery energy to the bronchial smooth muscle through an endoscopic approach. We tested these catheters in 2 acute canine studies and successfully demonstrated the ability to destroy smooth muscle tissue via novel prototypes and saline irrigation for widespread non-thermal electroporation ablation. Our functional studies demonstrate the efficacy of this approach. CONCLUSION: We report a novel method for non-thermal bronchial smooth muscle ablation using novel prototypes and electroporation with normal saline. These early findings require further evaluation in larger, chronic canine studies to assess for use as a potential curative therapy.
OBJECTIVE:Asthma is a common disease which places significant burden on the US healthcare system and which can be associated with significant patient morbidity and mortality. Current medical therapies are costly and not curative. A new approach for a more permanent asthma treatment is the use of radiofrequency ablation. However, this radiofrequency approach is thermal-based and can result in deleterious effects to the airways, such as stenosis or ulceration. We describe a novel, improved therapeutic approach for smooth muscle ablation using non-thermal DC electroporation ablation. METHODS: We developed and tested prototype electroporation ablation devices that access the airways both endoscopically and via a bronchoscope. We tested the feasibility of this approach and demonstrated proof-of-concept in 2 mongrel dogs. In order to assess for smooth muscle function, we performed functional studies pre and post ablation with methacholine challenge to assess for airway reversibility. We also evaluated bronchial lesions via direct vision with bronchoscopy. RESULTS: We developed novel electroporation catheters to delivery energy to the bronchial smooth muscle through an endoscopic approach. We tested these catheters in 2 acute canine studies and successfully demonstrated the ability to destroy smooth muscle tissue via novel prototypes and saline irrigation for widespread non-thermal electroporation ablation. Our functional studies demonstrate the efficacy of this approach. CONCLUSION: We report a novel method for non-thermal bronchial smooth muscle ablation using novel prototypes and electroporation with normal saline. These early findings require further evaluation in larger, chronic canine studies to assess for use as a potential curative therapy.
Authors: Jennifer L Trevor; Surya P Bhatt; J Michael Wells; deNay Kirkpatrick; Christopher Schumann; Jason Hitchcock; Mark T Dransfield Journal: J Asthma Date: 2015-08-18 Impact factor: 2.515
Authors: Mario Castro; Adalberto S Rubin; Michel Laviolette; Jussara Fiterman; Marina De Andrade Lima; Pallav L Shah; Elie Fiss; Ronald Olivenstein; Neil C Thomson; Robert M Niven; Ian D Pavord; Michael Simoff; David R Duhamel; Charlene McEvoy; Richard Barbers; Nicolaas H T Ten Hacken; Michael E Wechsler; Mark Holmes; Martin J Phillips; Serpil Erzurum; William Lunn; Elliot Israel; Nizar Jarjour; Monica Kraft; Narinder S Shargill; John Quiring; Scott M Berry; Gerard Cox Journal: Am J Respir Crit Care Med Date: 2009-10-08 Impact factor: 21.405
Authors: Andreas Müssigbrodt; Matthias Grothoff; Borislav Dinov; Jedrzej Kosiuk; Sergio Richter; Philipp Sommer; Ole A Breithardt; Sascha Rolf; Andreas Bollmann; Arash Arya; Gerhard Hindricks Journal: Biomed Res Int Date: 2015-01-29 Impact factor: 3.411